Amferia, a Swedish medtech leveraging antimicrobial peptides (AMPs) derived from the mammalian immune system to combat infections, believes its technology will reinforce the health care system’s “arsenal against bacteria.”
Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance
Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.
